Logo-jnp
J Nephropathol. 2017;6(2): 43-48. doi: 10.15171/jnp.2017.07
PMID: 28491851        PMCID: PMC5418068

Case Report

Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review

Tito Zattera 1, Francesco Londrino 2 * , Matteo Trezzi 1, Roberto Palumbo 2, Antonio Granata 3, Paola Tatangelo 2, Valentina Corbani 1, Valeria Falqui 1, Nadia Chiappini 1, Lisa Mathiasen 4, Marco Cavallini 5, Davide Rolla 1

Cited by CrossRef: 15

1- Matsubara T, Yokoi H, Yamada H, Yanagita M. Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists. Int J Clin Oncol. 2023;28(5):625 [Crossref]
2- Nagase K, Murai Y, Yokoyama-Kokuryo W, Nagasaka T, Sato Y, Watanabe T, Ito Y, Nagase F, Fujita Y. Renal Immune-related Adverse Event of Pembrolizumab Masked by Pemetrexed. Intern Med. 2024;63(2):265 [Crossref]
3- Naganuma M, Motooka Y, Sasaoka S, Hatahira H, Hasegawa S, Fukuda A, Nakao S, Shimada K, Hirade K, Mori T, Yoshimura T, Kato T, Nakamura M. Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database. SAGE Open Medicine. 2018;6:205031211877247 [Crossref]
4- Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair M, Powell S, Cheng S, Bischoff H, Peled N, Grossi F, Jennens R, Reck M, Hui R, Garon E, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray J, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza M, Garassino M. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078 [Crossref]
5- Storrar J, Woywodt A, Arunachalam C. AIN’t got no easy answers: recent advances and ongoing controversies around acute interstitial nephritis. 2019; [Crossref]
6- Yan X, Ma X, Hao Y, Liu J, Fang H, Lu D, Shen W, Zhang H, Ge W, Zhao Y. Alginate oligosaccharides ameliorate busulfan-induced renal tubule injury. Journal of Functional Foods. 2022;92:105048 [Crossref]
7- Sutandyo N, Wahyuni P, Kurniawati S, Tadjoedin H, Adella D. Cisplatin-induced Nephrotoxicty and its Predisposing Factors for Unrecovered Kidney Injury: A Report from Indonesia National Cancer Center. Open Access Maced J Med Sci. 2023;11(B):223 [Crossref]
8- Muto S, Matsubara T, Inoue T, Kitamura H, Yamamoto K, Ishii T, Yazawa M, Yamamoto R, Okada N, Mori K, Yamada H, Kuwabara T, Yonezawa A, Fujimaru T, Kawano H, Yokoi H, Doi K, Hoshino J, Yanagita M. Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol. 2023;28(10):1259 [Crossref]
9- Mense E, Smit A, Crul M, Franssen E. The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma. J Clin Pharm Ther. 2019;44(2):249 [Crossref]
10- Hałka J, Spaleniak S, Kade G, Antosiewicz S, Sigorski D. The Nephrotoxicity of Drugs Used in Causal Oncological Therapies. Current Oncology. 2022;29(12):9681 [Crossref]
11- Pemetrexed. Reactions Weekly. 2017;1647(1):237 [Crossref]
12- Santos M, Brito B, Silva F, Botelho A, Melo F. Nephrotoxicity in cancer treatment: An overview. WJCO. 2020;11(4):190 [Crossref]
13- Middleton G, Gridelli C, De Marinis F, Pujol J, Reck M, Ramlau R, Parente B, Pieters T, Visseren-Grul C, San Antonio B, John W, Zimmermann A, Chouaki N, Paz-Ares L. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Current Medical Research and Opinion. 2018;34(5):865 [Crossref]
14- de Rouw N, Boosman R, van de Bruinhorst H, Biesma B, van den Heuvel M, Burger D, Hilbrands L, ter Heine R, Derijks H. Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer. 2020;146:30 [Crossref]